Have a feature idea you'd love to see implemented?
Let us know!
TARA Protara Therapeutics Inc
Price (delayed)
$1.69
Market cap
$34.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.19
Enterprise value
-$49.73M
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based
Highlights
The equity has surged by 58% since the previous quarter and by 8% year-on-year
The EPS has increased by 46% year-on-year and by 15% since the previous quarter
Protara Therapeutics's quick ratio has soared by 58% from the previous quarter but it has decreased by 2.6% YoY
Key stats
What are the main financial stats of TARA
Market
Valuations
Earnings
Shares outstanding
20.63M
Market cap
$34.86M
Enterprise value
-$49.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$40.69M
EBITDA
-$40.34M
Free cash flow
-$33.42M
Per share
Balance sheet
Liquidity
EPS
-$3.19
Free cash flow per share
-$1.57
Book value per share
$4.47
Revenue per share
$0
TBVPS
$4.79
Total assets
$101.65M
Total liabilities
$9.6M
Debt
$4.98M
Equity
$92.05M
Working capital
$86.57M
Debt to equity
0.05
Current ratio
16.33
Quick ratio
15.86
Net debt/EBITDA
2.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.3%
Return on equity
-55%
Return on invested capital
-136.4%
Return on capital employed
-42.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARA stock price
How has the Protara Therapeutics stock price performed over time
Intraday
-2.87%
1 week
-4.52%
1 month
-8.15%
1 year
-1.17%
YTD
-10.11%
QTD
-7.65%
Financial performance
How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.25M
Net income
-$40.69M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 39% YoY and by 4.2% QoQ
TARA's operating income is up by 36% year-on-year and by 3.2% since the previous quarter
Growth
What is Protara Therapeutics's growth rate over time
Valuation
What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 46% year-on-year and by 15% since the previous quarter
The equity has surged by 58% since the previous quarter and by 8% year-on-year
TARA's P/B is 44% below its 5-year quarterly average of 0.7 and 22% below its last 4 quarters average of 0.5
Efficiency
How efficient is Protara Therapeutics business performance
TARA's return on invested capital has dropped by 59% year-on-year and by 37% since the previous quarter
The ROA has grown by 16% YoY and by 6% from the previous quarter
TARA's ROE is up by 14% year-on-year and by 6% since the previous quarter
Dividends
What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARA.
Financial health
How did Protara Therapeutics financials performed over time
Protara Therapeutics's quick ratio has soared by 58% from the previous quarter but it has decreased by 2.6% YoY
Protara Therapeutics's current ratio has soared by 55% from the previous quarter but it has decreased by 4.4% YoY
The debt is 95% less than the equity
The equity has surged by 58% since the previous quarter and by 8% year-on-year
Protara Therapeutics's debt to equity has decreased by 44% from the previous quarter and by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.